Benzinga | Jun 2, 2021 12:06PM EDT

Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial

* Eli Lilly And Co (NYSE:LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients.

* Discovered by Incyte Corporation (NASDAQ:INCY) and licensed to Lilly, Olumiant is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA in adults.

* Trial data showed that Olumiant also enhanced overall physical function at 12 weeks compared to adalimumab and placebo.

* The changes in pain relief were not affected by disease activity during treatment, Lilly noted.

* Furthermore, subjects receiving Olumiant had greater improvements in fatigue versus placebo, and the improvements were comparable to AbbVie Inc's (NYSE:ABBV) Humira after 12 weeks.

* Price Action: LLY shares are up 0.47% at $199.35 during the market session on the last check Wednesday.